Nevertheless, despite extensive preclinical evidence demonstrating the important of TOPK in tumor growth and progression, and the availability of multiple inhibitors capable of suppressing its kinase activity, there are currently no specific TOPK-targeted drugs approved for clinical use. The gene discussed is PBK; the disease is neoplasm.